How GLP-1 Telehealth Access Works

Telehealth programs for GLP-1 medications look simple from the outside: answer some questions, get a box in the mail. In practice, several separate parties are involved, and each has a job. Knowing who does what makes it easier to compare programs and to ask good questions.

The typical flow, step by step

Programs differ in the details, but most follow the same five steps.

1. Online intake

You complete a questionnaire about your height, weight, health history, and current medications. Answer it fully and honestly, because the clinician’s decision depends on it.

2. Licensed clinician review

A licensed clinician reviews your information. Some programs do this asynchronously, through forms and secure messages. Others use a video visit. Which format you get can depend on the program and on where you live.

3. Labs, if required

The clinician may ask for recent bloodwork, or may order new tests, before deciding. Some programs include this and others charge separately, so check before you sign up. Our costs page covers what a headline price can leave out.

4. Prescription decision

GLP-1s are prescription medications. If the clinician decides one is appropriate, they write a prescription. They may also decide it isn’t, and that is a sign the process is working as it should.

5. A pharmacy fills it and ships it

The telehealth company is usually not the pharmacy. A separate licensed pharmacy fills the prescription and ships it to you. You should be able to find out which one. Follow-up check-ins then let your clinician review your progress, your dose, and any side effects.

Typical eligibility screening

Only a licensed clinician can decide whether you’re eligible. What follows is general information about what clinicians commonly look at.

BMI thresholds

The National Institutes of Health says a health care professional may prescribe a weight management medication for an adult with a BMI of 30 or greater, or a BMI of 27 or greater with weight-related health problems such as high blood pressure or type 2 diabetes. FDA-approved labeling for semaglutide and tirzepatide weight management products describes adults with obesity, or adults with overweight and at least one weight-related condition. Those labels also say the medications are used along with a reduced-calorie diet and increased physical activity.

Medical history and contraindications

Both labels carry a boxed warning about thyroid C-cell tumors. Both say the medication should not be used by people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, or by people with a known hypersensitivity (allergic reaction) to its ingredients.

Expect questions about pregnancy plans as well, along with your other medications and past health conditions. The labels list more warnings than we can cover here, so go through your full history with the clinician.

Brand-name and compounded options

You may see two broad categories of product. They have different regulatory status.

FDA-approved brand-name medications

These have gone through FDA review for safety and effectiveness, and they come with FDA-approved labeling that describes their approved uses, dosing, and risks.

Compounded medications

Compounded drugs are not FDA-approved, and they are not the same as FDA-approved products. The FDA does not verify their safety, effectiveness, or quality before they are marketed. The FDA has reported adverse events that may be related to dosing errors, and it warns about fraudulent products with false information on the label.

The rules here are moving. The FDA has said semaglutide and tirzepatide are not on its drug shortage list. In April 2026 it proposed excluding both from the list of substances outsourcing facilities may compound from in bulk. We did not find a final decision as of our last check. The FDA has also said companies cannot claim compounded products are generic versions of, or the same as, FDA-approved drugs. Treat any such claim as a warning sign.

503A and 503B: what the terms mean

These labels come from two sections of the federal Food, Drug, and Cosmetic Act.

503A pharmacies: State-licensed pharmacies, or federal facilities, and licensed physicians that aren’t registered with the FDA as outsourcing facilities. Compounding must be based on a valid prescription for an identified patient. State boards of pharmacy have primary responsibility for overseeing them.
503B outsourcing facilities: Facilities registered with the FDA and primarily overseen by it. They must follow current good manufacturing practice requirements, and they may or may not obtain prescriptions for individual patients.

Neither category makes a product FDA-approved. FDA oversight of a 503B facility is not the same thing as FDA approval of what it makes.

Insurance and cash-pay

There are two main ways to pay, and many programs support one or both.

Insurance. Some, but not all, plans cover these medications, and the details depend on your plan and your reason for treatment. Among larger employers that offer health benefits, KFF found 18% of firms with 200 or more workers cover GLP-1s used primarily for weight loss in 2026. Call your insurer and ask whether the medication is covered, whether prior authorization is needed, and whether a telehealth prescriber is in network.

Cash-pay. You pay the program and medication costs yourself, without using insurance. That can be simpler, but you carry the full cost for as long as you stay on treatment. In a 2025 KFF poll, 56% of GLP-1 users said the drugs were difficult to afford.

We break down what programs charge on our costs page and compare them on our providers page.

How to spot a legit program

Good programs make these details easy to find. The FDA’s guide to buying medicines safely online says safe pharmacies always require a prescription, are licensed by a state board of pharmacy, have a licensed pharmacist available, and give a physical U.S. address and phone number.

Legit program checklist

Licensed U.S. clinicians review your information, and the program says so plainly.
A real prescription is required. There are no “no-prescription” offers.
A clinician can say no, and no one promises approval in advance.
The dispensing pharmacy is named, and you can check its license with your state board of pharmacy.
The product is clearly described as brand-name or compounded, with no claim that the two are the same.
All fees are listed, including labs, follow-ups, and medication.
Cancellation terms are clear and easy to find before you pay.
You can reach a real person, and you know how to contact a clinician with questions.

Red flags

Offers to sell a prescription medication without a prescription.
Guaranteed results or guaranteed approval.
Prices that seem too good to be true, which the FDA lists as a warning sign.
Calling a compounding pharmacy “FDA-approved” or “FDA-licensed.” The FDA has called such claims false and misleading.

Frequently asked questions

How does GLP-1 telehealth work?

You fill out an online health intake, and a licensed clinician reviews it, either through messages or a video visit. The clinician may ask for labs. If they decide a medication is appropriate, they write a prescription and a pharmacy ships it to you. Follow-up check-ins usually continue during treatment.

Do you need insurance for GLP-1 telehealth?

Not usually. Many telehealth programs accept cash payment, and some can work with your insurance. Coverage varies a lot by plan, so ask your insurer whether the medication is covered and what approvals it requires before you commit to anything.

Is online GLP-1 telehealth legit?

It can be. Legitimate programs use licensed clinicians, require a real prescription, name the pharmacy they use, and publish clear cancellation terms. Be wary of any site offering these medications without a prescription, because the FDA lists that as a warning sign for online pharmacies.

Will a telehealth clinician always prescribe a GLP-1?

No. A clinician decides based on your health history and may say a medication is not right for you. A program that promises approval before anyone has reviewed your information is a warning sign.

Are compounded GLP-1 products the same as FDA-approved medications?

No. Compounded medications are not FDA-approved and are not the same as FDA-approved products. The FDA does not review them for safety, effectiveness, or quality before they are marketed. Ask a licensed clinician to explain the differences.

Have more questions? See our full FAQ. If you’re in your 20s or early 30s, our guide for adults under 35 covers long-term planning and budgeting.

Sources

We read each of these pages on November 1, 2026. Rules and labeling change, so check the source for the current version.

Semaglutide injection and tablets prescribing information. DailyMed, U.S. National Library of Medicine, revised June 2026.
Tirzepatide injection prescribing information. DailyMed, U.S. National Library of Medicine, revised August 2026.
Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases (NIH), last reviewed June 2024.
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, current as of October 1, 2026.
Compounding and the FDA: Questions and Answers. U.S. Food and Drug Administration, current as of September 16, 2025.
FD&C Act Provisions that Apply to Human Drug Compounding. U.S. Food and Drug Administration, current as of August 13, 2021.
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration, current as of April 1, 2026.
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. U.S. Food and Drug Administration, April 30, 2026.
FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. U.S. Food and Drug Administration, February 6, 2026.
Warning letter to Momentum Health (MARCS-CMS 728286). U.S. Food and Drug Administration, June 8, 2026.
How to Buy Medicines Safely From an Online Pharmacy. U.S. Food and Drug Administration, current as of January 2, 2025.
2026 Employer Health Benefits Survey. KFF, October 22, 2026.
KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use. KFF, November 14, 2025.